This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial) (APOLLON)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2016 by Japan Regenerative Medicine Co., Ltd.
Sponsor:
Information provided by (Responsible Party):
Japan Regenerative Medicine Co., Ltd.
ClinicalTrials.gov Identifier:
NCT02781922
First received: May 19, 2016
Last updated: August 4, 2016
Last verified: June 2016
  Purpose
The purpose of this study is to evaluate the efficacy and safety of intracoronary injection of JRM-001 after reconstructive surgery in pediatric patients with functional single ventricle

Condition Intervention Phase
Hypoplastic Left Heart Syndrome Single Ventricle Genetic: Autologous cardiac stem cells (JRM-001) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study

Resource links provided by NLM:


Further study details as provided by Japan Regenerative Medicine Co., Ltd.:

Primary Outcome Measures:
  • Change in ejection fraction (EF(%)) assessed by MRI from baseline [ Time Frame: Baseline, 6 and 12 months ]

Secondary Outcome Measures:
  • Change in EF(%) assessed by echocardiograms from baseline [ Time Frame: Screening, Baseline, 3, 6 and 12 months ]
  • Change in EF(%) assessed by cardiac catheterization from baseline [ Time Frame: Baseline, 6 and 12 months ]
  • Change in Ea/Ees assessed by cardiac catheterization from baseline [ Time Frame: Baseline, 6 and 12 months ]
  • Change in Ventricular Stiffness assessed by cardiac catheterization from baseline [ Time Frame: Baseline, 6 and 12 months ]
  • Change in heart failure index from baseline [ Time Frame: Baseline, 3, 6 and 12 months ]
  • Change in Quality of Life (QOL) index from baseline [ Time Frame: Baseline, 6 and 12 months ]
  • Number of adverse events [ Time Frame: Up to 12 months ]

Estimated Enrollment: 40
Study Start Date: June 2016
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Autologous cardiac stem cells (JRM-001) Genetic: Autologous cardiac stem cells (JRM-001)
3x 10^5 cells/kg, single treatment
No Intervention: Usual care

  Eligibility

Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Functional single ventricle patient with heart failure who is scheduled for stage 2 (Glenn) or stage 3 (Fontan) surgery
  • EF(%) by echocardiography ≤ 55%
  • Able to obtain written informed consent of participation in the study by a parent of the patient

Exclusion Criteria:

  • Known medical history of cardiogenic shock
  • Lethal, uncontrollable arrhythmia
  • Complication of coronary artery disease
  • Eisenmenger syndrome
  • Complication of brain dysfunction due to circulatory failure
  • Malignant neoplasm
  • Complication of severe neurologic disorder
  • Severe pulmonary embolism or pulmonary hypertension
  • Severe renal failure
  • Multiple organ failure
  • Active infection (including endocarditis)
  • Sepsis
  • Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury)
  • Known history of hypersensitivity to anti-infective drugs
  • Inability to complete the protocol treatment and baseline to follow-up examinations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02781922

Locations
Japan
Kanagawa Children's Medical Center Recruiting
Yokohama, Kanagawa, Japan
Contact: Hideaki Ueda, M.D.    +81-45-711-2351      
Principal Investigator: Hideaki Ueda, M.D.         
Okayama University Recruiting
Okayama, Japan
Contact: Hidemasa Oh, M.D., Ph.D    +81-86-223-7151      
Principal Investigator: Hidemasa Oh, M.D., Ph.D         
Shizuoka Children's Hospital Recruiting
Shizuoka, Japan
Contact: Kisaburo Sakamoto, M.D.    +81-54-247-6251      
Principal Investigator: Kisaburo Sakamoto, M.D.         
Sponsors and Collaborators
Japan Regenerative Medicine Co., Ltd.
  More Information

Publications:
Responsible Party: Japan Regenerative Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT02781922     History of Changes
Other Study ID Numbers: 001-CLJ-001
Study First Received: May 19, 2016
Last Updated: August 4, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Japan Regenerative Medicine Co., Ltd.:
cardiac stem/progenitor cells
autologous cell therapy
functional single ventricle
congenital heart disease

Additional relevant MeSH terms:
Hypoplastic Left Heart Syndrome
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities

ClinicalTrials.gov processed this record on June 23, 2017